Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/428—Thiazoles condensed with carbocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

• the present invention relates to a crystalline form of lanifibranor, to pharmaceutical compositions containing said crystalline form, and to the use of said crystalline form in therapy.
• Lanifibranor or l-(6-benzothiazolylsulfonyl)-5-chloro-lH-indole-2-butanoic acid is a pan-PPAR agonist which is currently in clinical development for the treatment of patients with nonalcoholic steatohepatitis (NASH), for which there is currently no approved therapy.
• NASH nonalcoholic steatohepatitis
• Lanifibranor is described as the free base in example 117 of WO 2007/026097, where it is obtained as a pale yellow powder having a melting point of 74-80°C. Crystalline forms of lanifibranor are disclosed in WO 2022/122014, WO 2022/143479, WO 2022/258060, WO 2022/261410 and WO 2023/016319.
• the present invention provides a crystalline form of lanifibranor having desirable properties, such as high crystallinity, high purity, low hygroscopicity, favourable mechanical properties, and/or favourable stability.
• the invention provides a crystalline form of lanifibranor (form beta).
• Form beta of lanifibranor is characterized by one or more of the following methods: (1) powder X- ray diffraction (PXRD); (2) differential scanning calorimetry (DSC); (3) thermogravimetry (TGA); (4) dynamic vapor sorption (DVS); (5) infrared spectroscopy (IR).
• the invention provides a method for preparing crystalline form beta of lanifibranor, the method comprising heating a solution of lanifibranor in acetic acid and slowly cooling the resulting solution to room temperature.
• the invention provides a pharmaceutical composition
• a pharmaceutical composition comprising crystalline form beta of lanifibranor and a pharmaceutically acceptable carrier or excipient.
• the invention provides a method of treating non-alcoholic fatty liver disease, which comprises administering to a subject in need thereof an effective amount of crystalline form beta of lanifibranor.
• the invention provides a method of treating a cirrhotic subject at risk of progressing from compensated stage to decompensated stage, which comprises administering to the subject an effective amount of crystalline form beta of lanifibranor.
• the invention provides crystalline form beta of lanifibranor for use in a method of treating non-alcoholic fatty liver disease.
• the invention provides crystalline form beta of lanifibranor for use in a method of treating a cirrhotic subject at risk of progressing from compensated stage to decompensated stage.
• Figure 1 shows the PXRD pattern of form beta of lanifibranor.
• Figure 2 shows the DSC curve of form beta of lanifibranor.
• Figure 3 shows the TGA curve of form beta of lanifibranor.
• Figure 4 shows the DVS isotherm plot of form beta of lanifibranor.
• Figures 5A and 5B shows the IR spectrum of form beta of lanifibranor and the indexation of the absorption bands for the IR analysis.
• Figure 6 shows a comparison of PXRD patterns of amorphous form (bottom curve), form beta (middle curve), and form alpha (top curve) of lanifibranor.
• Figure 7 shows the DSC curve of form alpha of lanifibranor.
• Figure 8 shows a comparison of DSC curves of amorphous form (bottom curve), form beta (middle curve), and form alpha (top curve) of lanifibranor.
• Figures 9-14 show the PXRD patterns of a suspension of a mixture of lanifibranor forms alpha and beta in various solvents: acetone (figure 9), ethanol (figure 10), ethyl acetate (figure 11), acetic acid (figure 12), methyl ethyl ketone (figure 13) and methyl isobutyl ketone (figure 14).
• the top curve is the PXRD pattern of lanifibranor form alpha
• the top/middle curve is the PXRD pattern of the suspension at TO
• the middle/bottom curve is the PXRD pattern of the suspension at T0+24h
• the bottom curve is the PXRD pattern of lanifibranor form beta.
• Figure 15 shows the PXRD pattern of lanifibranor form alpha before (top curve) and after (bottom curve) compression.
• Figures 16-17 show a superimposition of the PXRD pattern of the solid form CSI described in WO 2022/122014 (bottom curve) with the PXRD pattern of lanifibranor form beta as shown in figure 1 (top curve).
• Figures 18-19 show a superimposition of the PXRD pattern of the solid form CSII described in WO 2022/122014 (bottom curve) with the PXRD pattern of lanifibranor form beta as shown in figure 1 (top curve).
• Figure 20 shows a superimposition of the PXRD pattern of the solid form CSIV described in WO 2022/122014 (bottom curve) with the PXRD pattern of lanifibranor form beta as shown in figure 1 (top curve).
• Figure 21 shows a superimposition of the PXRD patterns of the solid forms described in WO 2022/143479 with the PXRD pattern of lanifibranor form beta as shown in figure 1.
• lanifibranor form beta lanifibranor form beta
• lanifibranor cinnamamide co-crystal lanifibranor p-toluenesulfonic acid co-crystal
• lanifibranor tromethamine salt lanifibranor form A.
• Figure 22 shows a superimposition of the PXRD pattern of form A described in WO 2022/143479 (bottom curve) with the PXRD pattern of lanifibranor form alpha as shown in figure 1 (top curve).
• Figure 23 shows a superimposition of the PXRD patterns of solid forms CM-A, CM-B and CM- F described in WO 2022/258060 with the PXRD pattern of lanifibranor form beta as shown in figure 1.
• the following forms are represented, from top to bottom: lanifibranor form beta; form CM-A; form CM-B; form CM-F.
• Figure 24 shows a superimposition of the PXRD patterns of solid forms CM-C, CM-D, CM-E, CM-G and CM-I described in WO 2022/258060 with the PXRD pattern of lanifibranor form beta as shown in figure 1.
• the following forms are represented, from top to bottom: lanifibranor form beta; form CM-C; form CM-D; form CM-E; form CM-G; form CM-I.
• Figure 25 shows a superimposition of the PXRD patterns of solid forms LN-1, LN-2, LN-3 and LN-4 described in WO 2022/261410 with the PXRD pattern of lanifibranor form beta as shown in figure 1.
• the following forms are represented, from top to bottom: lanifibranor form beta; form LN-1; form LN-2; form LN-3; form LN-4.
• Figure 26 shows a superimposition of the PXRD pattern of form LN-1 described in WO 2022/261410 (bottom curve) with the PXRD pattern of lanifibranor form alpha as shown in figure 1 (top curve).
• Figure 27 shows a superimposition of the PXRD patterns of solid forms CSV (embodiments 2 and 3) and CSIII described in WO 2023/016319 with the PXRD pattern of lanifibranor form beta as shown in figure 1.
• the following forms are represented, from top to bottom: lanifibranor form beta; form CSV (embodiment 2); form CSV (embodiment 3); form CSIII.
• lanifibranor is understood to mean lanifibranor free acid, i.e. the compound of formula:
• the invention provides a crystalline form of lanifibranor (form beta).
• lanifibranor form beta was characterized by one or more of the following methods: (1) powder X-ray diffraction (PXRD); (2) differential scanning calorimetry (DSC); (3) thermogravimetry (TGA). Such crystalline form may be further characterized by additional techniques, such as: (4) dynamic vapor sorption (DVS); and (5) infrared spectroscopy (IR).
• PXRD powder X-ray diffraction
• DSC differential scanning calorimetry
• TGA thermogravimetry
• Such crystalline form may be further characterized by additional techniques, such as: (4) dynamic vapor sorption (DVS); and (5) infrared spectroscopy (IR).
• form beta of lanifibranor is characterized by its PXRD pattern.
• PXRD pattern X-ray diffraction peak positions (20)
• said positions will show some variability, typically as much as ⁇ 0.2°, such as for example ⁇ 0.1°.
• relative peak intensities will show inter-apparatus variability, as well as variability due to the degree of crystallinity, and should be taken as qualitative measures only.
• lanifibranor (form beta) is characterized by its DSC curve. In still other embodiments of each aspects of the invention, lanifibranor (form beta) is characterized by its TGA curve.
• lanifibranor (form beta) has a PXRD pattern comprising one, two, three, four, five or more than five peaks selected from the peaks in Table 1 (expressed in ° 20 ⁇ 0.2°).
• lanifibranor has a PXRD pattern comprising one or more peaks at 20 values selected from 16.0° ⁇ 0.2°, 18.7° ⁇ 0.2° and 24.6° ⁇ 0.2° 20, as measured using an X-ray wavelength of 1.5406
• form beta has a PXRD pattern further comprising at least one peak at 20 values selected from 11.4° ⁇ 0.2°, 18.0 ⁇ 0.2°, 21.2 ⁇ 0.2°, 22.8 ⁇ 0.2°, 23.5 ⁇ 0.2°, 26.1 ⁇ 0.2° and 26.7° ⁇ 0.2° 20, as measured using an X-ray wavelength of 1.5406 .
• the PXRD pattern further comprises one or more additional peaks at 20 values selected from the peaks in Table 1.
• the PXRD pattern of lanifibranor (beta form) is substantially in accordance with figure 1.
• lanifibranor (form beta) has a DSC curve comprising an endothermic peak at 182.3°C. In one embodiment, the DSC curve of lanifibranor (form beta) is substantially in accordance with figure 2.
• the TGA curve of lanifibranor does not highlight any significant weight loss over the temperature range 25 - 200°C. Above 250°C, the weight loss observed likely corresponds to degradation.
• the TGA curve of lanifibranor (form beta) is substantially in accordance with figure 3.
• the DVS analysis performed on lanifibranor (form beta) does not exhibit significant weight variations over the range of relative humidity values investigated: a maximum uptake of + 0.1% was observed on the range 0% RH - 95% RH .
• the DVS isotherm plot of lanifibranor (form beta) is substantially in accordance with figure 4.
• the IR spectrum of lanifibranor (form beta) is substantially in accordance with figure 5.
• the invention provides a method for preparing lanifibranor (form beta), the method comprising a) heating a solution of lanifibranor in acetic acid, at a temperature in the range of about 100°C to about 110°C, and b) cooling the resulting solution to room temperature.
• step a) is performed at a temperature of about 105°C.
• step a) and step b), as defined above, are repeated at least once.
• the method for preparing lanifibranor (form beta) may comprise the steps of:
• Lanifibranor free acid can be obtained e.g. as described in WO 2007/026097 or as described in example 1 below.
• Lanifibranor form beta can be used as the active ingredient of a pharmaceutical composition.
• the invention provides a pharmaceutical composition comprising lanifibranor (form beta) and a pharmaceutically acceptable carrier or excipient.
• pharmaceutically acceptable carrier or excipient means that the excipient or carrier is suitable for incorporation into a pharmaceutical composition and is compatible with the other ingredients of the composition. Particularly, it is not toxic. Its use allows facilitating the preparation, preservation and administration of the active ingredient.
• excipients and carriers are well-known to the person skilled in the art, and are described in the French and/or European Pharmacopoeia.
• Examples of pharmaceutical carriers include, but not limited to, any suitable solvents, dispersion media, coatings, antibacterial and antifungal agents and isotonic agents, and examples of excipients that may also be components of the formulation include fillers, binders, disintegrating agents and lubricants.
• the invention provides a method of treating non-alcoholic fatty liver disease (NAFLD), which comprises administering to a subject in need thereof an effective amount of lanifibranor (form beta).
• NAFLD non-alcoholic fatty liver disease
• NAFLD includes non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH).
• the invention provides a method of treating a cirrhotic subject at risk of progressing from compensated stage to decompensated stage, which comprises administering to the subject an effective amount of lanifibranor (form beta).
• the invention provides lanifibranor form beta for use in a method of treating non-alcoholic fatty liver disease.
• the invention provides lanifibranor form beta for use in a method of treating a cirrhotic subject at risk of progressing from compensated stage to decompensated stage.
• NAFLD non-alcoholic fatty liver disease
• the invention provides for the use of lanifibranor form beta as defined above for the preparation of a medicament intended for the treatment of cirrhosis in compensated stage, especially for preventing the decompensation of cirrhosis.
• MeTHF 2-methyl tetra hydrofuran
• NAC N-acetyl-L-cysteine
• PdCl2(PPh 3 ) 2 bis(triphenylphosphine)palladium(II) dichloride
• DSC analysis was conducted on a Mettler Toledo DSC3+ calorimeter. Analyses were performed on a few milligrams of sample, in 40 pL sealed aluminum pans, punctured before analysis, under nitrogen flush at 50 mL/min. A temperature range between 20°C and 300°C was scanned at a 10°C/min rate.
• TGA analysis was conducted on a Mettler Toledo TGA/DSC3+ thermogravimetric analyzer. Analyses were performed on a few milligrams of sample, in 100 pL sealed aluminum pans, punctured before analysis, under nitrogen flush at 50 mL/min. A temperature range between 25°C and 300°C was scanned at a 10°C/min rate.
• DVS analysis was conducted on a SMS DVS Intrinsic system. Analyses were performed on a few milligrams of sample, in open aluminum pans at 25°C. The stability criterion for each step was a weight change lower than 0.002% on a 5 min time frame. The time criterion for each step was 100 min (minimum duration by step: 10 min). Relative humidity was scanned between 0% RH and 95% RH with 10% RH steps (40 - 0 - 95 - 0 - 95).
• IR analysis was conducted on a NicoletTM iS5 spectrometer equipped with an ATR iD7 accessory. Analyses were performed in ATR mode from 4000 cm 1 to 525 cm 1 (resolution of 4 cm 1 ), with 32 scans for background and measurement.
• the mixture was washed with MTBE (2 volumes) 3 times.
• the aqueous phase was treated with a mixture of MeTHF and HCI (37%).
• the MeTHF solution was washed with a 6% aqueous solution of NAC (twice).
• the washing was performed by stirring the organic phase with 20% w/w of NAC at 60°C for 1 hour.
• the organic phase was then washed twice and the NAC phases were combined and washed with pure water (three times). As previously, the washing was performed by stirring the NAC phase with water at 60°C for 1 hour.
• the MeTHF solution was heated at 60°C.
• the solution obtained in example 1 was concentrated. Acetic acid was added to the residue and the solution was concentrated. The suspension was heated at 105°C, and acetic acid was added in small portions until complete dissolution. The solution was then stirred at 105°C for 1 hour, and left to slowly cool down to room temperature under stirring. The solid product obtained was filtered on a sintered glass G4 filter and washed twice with acetic acid to give 41.63 g of product (86.3% yield) with a HPLC purity of 99.8%. 41.3 g of product were suspended in acetic acid and the suspension was stirred at 105°C for 1 hour.
• Form beta of lanifibranor was characterized by PXRD (figure 1), DSC (figure 2), TGA (figure 3), DVS (figure 4) and IR (figures 5A and 5B). It can be seen from figure 2 that lanifibranor (form beta) has a DSC curve comprising an endothermic peak at 182.3°C.
• a homogenous solution was prepared by dissolving form beta of lanifibranor (10g), as obtained in example 2, in acetic acid (7.5 volumes) at 98°C. The solution was then quenched by stirring the mixture at 5°C under precipitation occurred. The temperature of the mixture was monitored and, once it reached 20°C, the solid phase was recovered by filtration on n°3 sintered glass filter. The solid recovered was dried at 60°C under vacuum and kept at room temperature.
• Form alpha of lanifibranor was characterized by PXRD (Table 2 and figure 6) and DSC (figure 7). It can be seen from figure 7 that form alpha has a DSC curve comprising an endothermic peak at 180.8°C. Table 2
• a homogenous solution was prepared by dissolving 1 g of lanifibranor (form beta), as obtained in example 2, in 35 mL of acetone, at 50°C. The solution was then fully evaporated under vacuum at 50°C. The solid phase was then recovered, dried overnight under vacuum, at room temperature, and stored at -26°C.
• the amorphous form of lanifibranor was characterized by PXRD (see figure 6).
• a saturated solution of lanifibranor form beta (as obtained in example 2) was prepared for each solvent.
• An equal amount of lanifibranor form alpha and lanifibranor form beta was introduced into a vial (50 mg + 50 mg), and 250 pL of the saturated solution prepared beforehand (recovered by filtration through a 0.2 pm H-PTFE filter) were then added.
• the mixture was stirred at room temperature, samples of the solid were taken immediately after stirring was initiated and 24 hours after, and analyzed by PXRD to identify the solid form(s) present.
• the results are presented in Table 2.
• Example 8 comparison between lanifibranor form beta and lanifibranor as obtained in example 117 of WO 2007/026097
• Lanifibranor was prepared following the procedure described in example 117 of WO 2007/026097. A white amorphous powder was obtained in about 75% yield, with a melting point (measured on a Kofler bench) in the range 74-76°C. The product obtained was found to be amorphous, with a PXRD pattern comparable to that shown in Figure 6.
• Example 9 comparison between lanifibranor form beta and the solid forms disclosed in WO 2022/122014
• the PXRD patterns of the solid forms described in WO 2022/143479 namely lanifibranor cinnamamide co-crystal (examples 1-6), lanifibranor p-toluenesulfonic acid co-crystal (examples 7-11), lanifibranor tromethamine salt (examples 12-16), and form A (examples 17-20), were digitized and then compared (by superimposition) to the PXRD pattern of lanifibranor form beta (as shown in figure 1). The results are shown in figure 21.
• Example 11 comparison between lanifibranor form beta and the solid forms disclosed in WO 2022/258060
• the PXRD patterns of the solid forms described in WO 2022/258060 namely lanifibranor solid forms CM-A, CM-B, CM-C, CM-D, CM-E, CM-F, CM-G and CM-I, were digitized and then compared (by superimposition) to the PXRD pattern of lanifibranor form beta (as shown in figure 1).
• the results are shown in figure 23 (forms CM-A, CM-B and CM-F) and figure 24 (forms CM-C, CM-D, CM-E, CM-G and CM-I).
• Example 12 comparison between lanifibranor form beta and the solid forms disclosed in WO 2022/261410
• the PXRD patterns of the solid forms described in WO 2022/261410 were digitized and then compared (by superimposition) to the PXRD pattern of lanifibranor form beta (as shown in figure 1). The results are shown in figure 25. It can be concluded from this figure that none of the PXRD patterns described in WO 2022/261410 match with the PXRD pattern of lanifibranor form beta. By contrast, and as shown in figure 26, the PXRD pattern of form LN-1 described in WO 2022/261410 substantially matches with the PXRD pattern of lanifibranor form alpha (as shown in figure 6).
• Example 13 comparison between lanifibranor form beta and the solid forms disclosed in WO 2023/016319
• the PXRD patterns of the solid forms described in WO 2023/016319 were digitized and then compared (by superimposition) to the PXRD pattern of lanifibranor form beta (as shown in figure 1). The results are shown in figure 27. It can be concluded from this figure that none of the PXRD patterns described in WO 2023/016319 match with the PXRD pattern of lanifibranor form beta. In addition, the PXRD patterns of the solid forms described in WO 2023/016319 do not match either with the PXRD pattern of lanifibranor form alpha (data not shown).
• the drug substance was characterized by PXRD and by DSC.
• the PXRD pattern was characteristic of lanifibranor form beta as shown in figure 1
• the DSC curve was characteristic of lanifibranor form beta (endothermic peak at 182.3°C), indicating that lanifibranor form beta is stable over long-term storage.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Gastroenterology & Hepatology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Saccharide Compounds (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=81326293

Family Applications (1)

Country Status (14)

Cited By (9)

Citations (6)

• 2023
  • 2023-03-31 TW TW112112450A patent/TW202404966A/zh unknown
  • 2023-04-04 EP EP23717474.3A patent/EP4504725A1/en active Pending
  • 2023-04-04 US US18/854,287 patent/US20250243192A1/en active Pending
  • 2023-04-04 WO PCT/EP2023/058743 patent/WO2023194339A1/en not_active Ceased
  • 2023-04-04 AR ARP230100832A patent/AR128985A1/es unknown
  • 2023-04-04 IL IL316075A patent/IL316075A/en unknown
  • 2023-04-04 AU AU2023250118A patent/AU2023250118A1/en active Pending
  • 2023-04-04 KR KR1020247036771A patent/KR20250002337A/ko active Pending
  • 2023-04-04 PY PY202302324870A patent/PY2324870A/es unknown
  • 2023-04-04 CA CA3247273A patent/CA3247273A1/en active Pending
  • 2023-04-04 JP JP2024559386A patent/JP2025511847A/ja active Pending
  • 2023-04-04 CN CN202380042246.2A patent/CN119301120A/zh active Pending
  • 2023-04-10 UY UY0001040216A patent/UY40216A/es unknown
• 2024
  • 2024-10-04 MX MX2024012348A patent/MX2024012348A/es unknown

Patent Citations (6)

Also Published As

Similar Documents

Legal Events